Free Trial
LON:POLB

Poolbeg Pharma (POLB) Share Price, News & Analysis

Poolbeg Pharma logo
GBX 5.90 +0.08 (+1.37%)
As of 11:41 AM Eastern

About Poolbeg Pharma Stock (LON:POLB)

Advanced

Key Stats

Today's Range
5.80
▼
6.30
50-Day Range
5.77
▼
9.30
52-Week Range
3.30
▼
9.30
Volume
1.01 million shs
Average Volume
1.91 million shs
Market Capitalization
£45.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.

Receive POLB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Poolbeg Pharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

POLB Stock News Headlines

Already up 111%, is this penny stock about to double again?!
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
POLB001 CRS Patent Granted in South Korea
Poolbeg Pharma Secures South Korean Patent for POLB 001
See More Headlines

POLB Stock Analysis - Frequently Asked Questions

Poolbeg Pharma's stock was trading at GBX 4 on January 1st, 2026. Since then, POLB shares have increased by 47.5% and is now trading at GBX 5.90.

Poolbeg Pharma PLC (LON:POLB) released its quarterly earnings data on Tuesday, September, 29th. The company reported GBX (0.28) earnings per share for the quarter.

Shares of POLB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Company Calendar

Last Earnings
9/29/2026
Today
11/16/2026

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
LON:POLB
CIK
N/A
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
GBX (0.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-£4.50 billion
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-71.28%
Return on Assets
-21.33%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.44
Quick Ratio
47.96

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
GBX 2.80 per share
Price / Cash Flow
2.11
Book Value
GBX 2,489.80 per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
763,437,000
Free Float
N/A
Market Cap
£45.04 million
Optionable
Not Optionable
Beta
1.84
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (LON:POLB) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners